Ahmed S. Eldessouky

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Dear Editor, Cosman et al. evaluate the efficacy of romosozumab, in phase III trials [1]. Romosozumab belongs to a new class of antiresorptive: the AMARTs (antibody mediated anti-resorptive therapy); of which RANKL-inhibitor, denosumab, is the most widely used [2]. As an anti-sclerost in antibody, romosozumab, is the first of this AMART-subclass to reach(More)
  • 1